NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 5, 2021 | Post-IPO Equity | $200M | 13 | — | — | Detail |
Dec 22, 2016 | Post-IPO Debt | $150M | — | — | — | Detail |
Mar 30, 2009 | Post-IPO Equity | $500K | — | — | — | Detail |
Nov 12, 1999 | IPO | $34.60M | — | — | — | Detail |
NeoGenomics has had 1 exits. NeoGenomics most notable exits include Inivata
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
May 5, 2021 | Inivata | M&A | Biotechnology | Detail |
NeoGenomics has acquired 5 organizations. Their most recent acquisition was Path Logic on Jul 8, 2014. They acquired Path Logic for $6M.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jul 8, 2014
Path Logic
|
Biotechnology | acquisition | $ 6M | Detail |
Oct 21, 2015
Clarient
|
Biotechnology | acquisition | — | Detail |
Oct 23, 2018
Genoptix
|
Communities | acquisition | — | Detail |
Mar 24, 2021
Trapelo Health
|
Health Care | acquisition | $ 65M | Detail |
May 5, 2021
Inivata
|
Biotechnology | acquisition | — | Detail |